Citations

Clear

28 citation(s) found for "Sayegh, J".

Spirulina (Arthrospira platensis) Improved Nonalcoholic Fatty Liver Disease Characteristics and Microbiota and Did Not Affect Organ Fibrosis Induced by a Fructose-Enriched Diet in Wistar Male Rats
Fakhoury-Sayegh, Nicole , Hamdan, Aya , Lebbos, Sarah, Trak-Smayra, Viviane , Khazzaka, Aline , Dagher‐Hamalian, Carole , Sayegh, Lea N. , Mallah, May , Obeid, Omar , Sayegh, Raymond, Khazzaka, Aline , Sayegh, Lea Nicole , Itani, Tarek M.

Mayo Clinic

Nutrients | May 30, 2024 | Volume: 16 | Issue: 11 | Pages: 1701

10.3390/nu16111701 | PMID 38892633 Get It

Spirulina (Arthrospira platensis) is reported to play a role in improving nonalcoholic fatty liver disease (NAFLD) and intestinal microbiota (IM). To study spirulina’s effects in the improvement of NAFLD characteristics, IM, and pancreatic–renal lesions induced by a fructose-enriched diet, 40 Wistar healthy male rats, weighing 200–250 g, were randomly divided into four groups of 10, and each rat per group was assigned a diet of equal quantities (20 g/day) for 18 weeks. The first control group (CT) was fed a standardized diet, the second group received a 40% fructose-enriched diet (HFr), and the third (HFr-S5) and fourth groups (HFr-S10) were assigned the same diet composition as the second group but enriched with 5% and 10% spirulina, respectively. At week 18, the HFr-S10 group maintained its level of serum triglycerides and had the lowest liver fat between the groups. At the phylae and family level, and for the same period, the HFr-S10 group had the lowest increase in the Firmicutes/Bacteroidetes ratio and the Ruminococcaceae and the highest fecal alpha diversity compared to all other groups (p < 0.05). These findings suggest that at a 10% concentration, spirulina could be used in nutritional intervention to improve IM, fatty liver, metabolic, and inflammatory parameters associated with NAFLD.
Evaluation of ctDNA in patients with mCRPC with liver metastases.
Huang, Minqi, Casado, Crystal, Habibian, Nicholas , Akerele, Opeoluwa Abraham, Gupta, Kanika, Lieberman, Alexandra, Schwartz, Jennifer, Layton, Jodi Lyn , Sweeney, Patrick L. , Lewis, Brian, Gebrael, Georges , Sayegh, Nicolas , Agarwal, Neeraj , Sartor, Oliver , Ledet, Elisa M.

Mayo Clinic

Journal of Clinical Oncology | January 29, 2024 | Volume: 42 | Issue: 4_suppl | Pages: 212-212

10.1200/jco.2024.42.4_suppl.212 Get It

212 Background: Patients with prostate cancer with liver metastases are known to have a worse prognosis. In this study, we evaluated ctDNA in mCRPC (metastatic castration-resistant prostate cancer) patients with and without liver metastases. Methods: A retrospective chart review identified mCRPC patients with liver metastases at Tulane Cancer Center and Huntsman Cancer Institute. Liver metastases were confirmed via molecular or conventional imaging. All patients had ctDNA assessed with a multi-gene cancer panel via the Guardant 360 assay. Alterations with <0.1% allelic fraction, synonymous alterations, and variants of unknown significance were excluded from analyses. Statistical analyses were performed using Fisher’s Exact and Wilcoxon Rank Sum Tests. Correction for multiple testing was not performed, hence these alterations may be subject to a type 1 error. Results: 53 mCRPC patients with liver metastases and 144 mCRPC patients without liver metastases were included in the study. We found seven genes that are more likely to be pathologically altered in ctDNA in mCRPC patients with liver metastases (See Tables 1-3): AR (OR=2.38, 95% CI: [1.25, 4.52], p=0.01), BRAF (OR=2.74, 95% CI:[1.05, 7.18], p=0.05), BRCA2 (OR=5.33, 95% CI:[1.49, 19.02], p=0.01), CDK6 (OR=4.09, 95% CI:[1.35, 12.42], p=0.01), EGFR (OR=3.12, 95% CI:[1.22, 7.99], p=0.02), FGFR1 (OR=5.69, 95% CI:[1.81, 17.86], p-value=0.003), MYC (OR=4.55, 95% CI:[1.63, 12.68], p=0.004), and PIK3CA (OR=4.34, 95% CI:[1.87, 10.06], p=0.01). Additionally, mCRPC patients with liver metastases are more likely to have copy number alterations (CNA) (p= 0.01) compared to mCRPC patients without liver involvement. There were no other significant differences in the remaining 70 genes interrogated. Germline pathogenic alterations did not vary between the two groups. Conclusions: In mCRPC patients with liver metastases, these exploratory analyses suggest ctDNA testing is more likely to detect pathologic alterations in AR, BRAF, BRCA2, CDK6, EGFR, FGFR1, MYC, and PIK3CA. Additionally, mCRPC patients were more likely to have copy number alterations (CNA). Limitations of the Guardant 360 assays are notable in this setting given the incomplete ascertainment of gene deletions and the incomplete number of prostate-relevant genes assessed. [Table: see text]
S1231 Predictors of Successful Stone Fragmentation and Extraction Using Electrohydraulic Lithotripsy: A Multicentric Study
Sayegh, Lea N. , Akiki, Karl, Salame, Marita , Annan, Karim Al , Winkie, Mason, Kolachana, Sindhura, Yohannan, Ethan David, Marya, Neil B. , Pawa, Swati , Kim, Raymond , Akiki, Karl, Fadel, Anthony , Achebe, Ikechukwu , Canakis, Andrew , Marya, Neil B. , Pawa, Rishi , Storm, Andrew C.

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S940-S941

10.14309/01.ajg.0000954564.56753.77 Get It

Hemosuccus Pancreaticus: Diagnostic Pitfalls of a Rare Condition
Busebee, Bradley , AT, Kurdi, BR, Stultz, LN, Sayegh, Busebee, Brad , Kurdi, Ahmed T. , Stultz, Benjamin R. , Sayegh, Lea N. , Coelho–Prabhu, Nayantara

Mayo Clinic

ACG Case Reports Journal | March 23, 2023 | Volume: 10 | Issue: 3 | Pages: e01014

10.14309/crj.0000000000001014 | PMID 36998341 Get It

ABSTRACT The combination of cirrhosis and chronic pancreatitis is rare and poses increased risk of hemorrhage requiring close clinical monitoring. We present a patient with history of alcohol-associated cirrhosis and chronic pancreatitis who was admitted to the intensive care unit with clinical hemorrhage believed secondary to epistaxis. After initial delay, esophagogastroduodenoscopy ultimately found blood and clots evacuating through the ampulla consistent with hemosuccus pancreaticus confirmed with computed tomography angiography. The patient ultimately improved with coil and gel foam vascular embolization. This case highlights the dangers of early diagnostic closure and presents a rare finding of hemosuccus without pseudoaneurysm formation.
Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer
Su, Christopher , Nizialek, Emily , Berchuck, Jacob E. , Vlachostergios, Panagiotis J. , Ashkar, Ryan, Sokolova, Alexandra , Aggarwal, Rahul , McKay, Rana R. , Nafissi, Nellie , Bryce, Alan H. , Taplin, Mary‐Ellen , Cieślik, Marcin , Alva, Ajjai , Antonarakis, Emmanuel S. , Antonarakis, Emmanuel S. , Su, Christopher , Nafissi, Nellie N , Bryce, Alan H , Sartor, A Oliver , Sayegh, Nicolas , Cheng, Heather H , Antonarakis, Emmanuel S , Vlachostergios, Panagiotis J , Antonarakis, Emmanuel S , Barata, Pedro C. , Agarwal, Neeraj , McClure, Heather M. , Sartor, Oliver , Cheng, Heather H. , Adra, Nabil , Sternberg, Cora N

Mayo Clinic

The Prostate | November 16, 2022 | Volume: 83 | Issue: 3 | Pages: 227-236

10.1002/pros.24454 | PMID 36382533 Get It

AbstractBackgroundPARP (poly(ADP‐ribose) polymerase) inhibitors (PARPi) are now standard of care in metastatic castrate‐resistant prostate cancer (mCRPC) patients with select mutations in DNA damage repair (DDR) pathways, but patients with ATM‐ and BRCA2 mutations may respond differently to PARPi. We hypothesized that differences may also exist in response to taxanes, which may inform treatment sequencing decisions.MethodsmCRPC patients (N = 158) with deleterious ATM or BRCA2 mutations who received taxanes, PARPi, or both were retrospectively identified from 11 US academic centers. Demographic, treatment, and survival data were collected. Kaplan−Meier analyses were performed and Cox hazard ratios (HR) were calculated for progression‐free survival (PFS) as well as overall survival (OS), from time of first taxane or PARPi therapy.ResultsFifty‐eight patients with ATM mutations and 100 with BRCA2 mutations were identified. Fourty‐four (76%) patients with ATM mutations received taxane only or taxane before PARPi, while 14 (24%) received PARPi only or PARPi before taxane. Patients with ATM mutations had longer PFS when taxane was given first versus PARPi given first (HR: 0.74 [95% confidence interval [CI]: 0.37−1.50]; p = 0.40). Similarly, OS was longer in patients with ATM mutations who received taxane first (HR: 0.56 [CI: 0.20−1.54]; p = 0.26). Among patients with BRCA2 mutations, 51 (51%) received taxane first and 49 (49%) received PARPi first. In contrast, patients with BRCA2 mutations had longer PFS when PARPi was given first versus taxane given first (HR: 0.85 [CI: 0.54−1.35]; p = 0.49). Similarly, OS was longer in patients with BRCA2 mutations who received PARPi first (HR: 0.75 [CI: 0.41−1.37]; p = 0.35).ConclusionsOur retrospective data suggest differential response between ATM and BRCA2 mutated prostate cancers in terms of response to PARPi and to taxane chemotherapy. When considering the sequence of PARPi versus taxane chemotherapy for mCRPC with DDR mutations, ATM, and BRCA2 mutation status may be helpful in guiding choice of initial therapy.
Real-world prevalence of homologous recombination repair gene (BRCA1/2 and ATM) mutations (HRRm) in patients (pts) with advanced prostate cancer (aPC) as detected by comprehensive genomic profiling (CGP) of circulating cell-free DNA (cfDNA).
Swami, Umang , Lilly, Michael B. , Hensel, Chuck, Bilen, Mehmet Asım , Heath, Elisabeth I. , Nandagopal, Lakshminarayanan , Vaena, Daniel A. , Pal, Sumanta K. , Sayegh, Nicolas , Barata, Pedro C. , Nussenzveig, Roberto , Hensel, Chuck, Bryce, Alan H. , Garje, Rohan , Saylor, Philip J. , Babiker, Hani M. , Kohli, Manish , Sartor, Oliver , Agarwal, Neeraj

Mayo Clinic

Journal of Clinical Oncology | March 2, 2021 | Volume: 39 | Issue: 6_suppl | Pages: 256-256

10.1200/jco.2021.39.6_suppl.256 Get It

256 Background: PARP inhibitors, olaparib and rucaparib recently improved survival outcomes (in the Profound and Triton-2 trials) in pts with aPC harboring HRRm. Notably, ~35% of pts screened for the PROfound trial did not meet eligibility solely due to the lack of adequate quality/quantity of tumor tissue required for CGP (De Bono, NEJM, 2020). cfDNA analysis non-invasively assesses tumor-derived genomic alterations. We evaluated the prevalence of HRRm in a real-world aPC population, who had commercially available cfDNA assay results available. Methods: cfDNA based CGP (using a clinically-validated 73- to 74-gene panel i.e. Guardant360 or G360) from consecutive aPC pts between 11/2016–8/2020 were used for detection of HRRm. Frameshift and nonsense mutations were included as pathogenic. Variants of unknown significance were excluded. In this unmatched study, the prevalence of each HRRm was compared with those reported in literature using the chi square test. Results: cfDNA CGP from 7701 aPC pts were available for interrogation of BRCA1/BRCA2 mutations, & from 4671 aPC pts for ATM mutations. Prevalence of BRCA1 and 2 as detected by cfDNA was similar to historical CGP of primary tissue. Prevalence of BRCA1 was higher than historical CGP of metastatic tissue. Prevalence of ATM in cfDNA was higher than historic tumor tissue CGP but similar to prior reports from cfDNA testing (Table). Conclusions: In this large real-world population of pts with aPC undergoing routine cfDNA CGP by a CLIA certified lab, prevalence of HRRm was similar (or higher for BRCA1 and ATM) to what has been previously reported from the tumor tissue. These data provide the rationale for utilizing cfDNA CGP as a routine test for detection of HRRm in men with aPC to identify men who are candidates for PARPi. [Table: see text]
Feasibility and acceptability of the “Day 100 Talk”: An interdisciplinary communication intervention during the first six months of childhood cancer treatment
Feraco, Angela M. , McCarthy, Sarah , Revette, Anna , Stevens, Sarah E. , Das, Porag Jeet , Ma, Clement , Tulsky, James A. , McCarthy, Sarah R. , McCarthy, Sarah R , Al‐Sayegh, Hasan , Wolfe, Joanne , McCarthy, Sarah R.

Mayo Clinic

Cancer | December 20, 2020 | Volume: 127 | Issue: 7 | Pages: 1134-1145

10.1002/cncr.33362 | PMID 33320337 Get It

BackgroundCommunication gaps arise early in the childhood cancer trajectory and may persist. The authors conducted a pilot study of the feasibility and acceptability of a communication intervention, the Day 100 Talk (D100). D100 involves an interprofessional family conference during initial months of treatment between oncologists, psychosocial clinicians, and parents, facilitated by a 3‐part conversation tool.MethodsThe authors enrolled English‐speaking parents of children with nonrelapsed, nonprogressive cancer who were receiving continuity care from enrolled pediatric oncologists and psychosocial clinicians at a single site. The a priori feasibility threshold was 60% parent completion of the D100 intervention. Surveys from parents and professionals and debrief interviews with professionals assessed D100 acceptability.ResultsThirty‐seven parents (77%) and 38 oncology professionals (67%) enrolled. Twenty of 33 evaluable parents (61%) participated in a D100 family conference. Most commonly, parents did not complete the D100 intervention because of scheduling difficulties related to clinical team constraints. All 17 parents who completed a post‐D100 survey agreed or strongly agreed that D100 participation was helpful. In debrief interviews, professionals identified D100 benefits, namely, stepping back to the big picture and getting on the same page, and barriers related to logistical challenges and professionals' anticipatory dread.ConclusionsThe D100 intervention pilot demonstrates high acceptability among parents of children with cancer. Despite meeting the prespecified feasibility threshold, findings highlight important barriers to D100 dissemination, namely, perceived burdens on professionals. Potential strategies to reduce burden may include using virtual visit platforms, incorporating D100 elements across multiple visits, or prioritizing intervention delivery to parents with the greatest need for enhanced communication.
Facial Masculinization Surgery and its Role in the Treatment of Gender Dysphoria
Sayegh, Farah , Ludwig, David C. , Ascha, Mona , Vyas, Krishna S. , Shakir, Afaaf , Kwong, Jeffrey W. , Swanson, Marco , Evans, Morgan W., Gatherwright, James , Evans, Morgan W., Morrison, Shane D.

Mayo Clinic

Journal of Craniofacial Surgery | January 26, 2019 | Volume: 30 | Issue: 5 | Pages: 1339-1346

10.1097/scs.0000000000005101 | PMID 31299718 Get It

Background: Interest in facial masculinization surgery is expected to increase as gender-affirming surgery becomes more widely accepted and available. The purpose of this study is to summarize the current literature describing operative techniques in facial masculinization surgery and provide an algorithmic approach to treating this patient population. Methods: PubMed, EMBASE, and Medline databases were queried for literature on operative techniques and outcomes of facial masculinization surgery in transgender and cisgender patients, published through July 2018. Data on patient demographics, follow-up, operative techniques, complications, and outcomes were collected. Results: Fifteen of the 24 identified studies met inclusion criteria. Two studies discussed the outcomes of 7 subjects (6 trans-male and 1 cis-male) who underwent facial masculinization procedures. No objective outcomes were reported in either study; however, subjects were generally satisfied and there were no complications. The remaining studies reviewed operative techniques utilized in the cisgender population. Conclusion: A summary of considerations for each facial anatomic subunit and respective operative techniques for facial masculinization is presented. Current facial masculinization procedures in cisgender patients may be considered in the transgender patient population with favorable outcomes. However, further research is needed on techniques and objective outcome measures of facial masculinization procedures in the transgender population.